卡瑞利珠单抗联合化疗治疗晚期食管鳞状细胞癌的近期疗效观察  

Observation on short-term efficacy of camrelizumab combined with chemotherapy in the treatment of advanced esophageal squamous cell carcinoma

作　　者：马春明 MA Chun-ming(Oncology Department,Yingkou Traditional Chinese Medicine Hospital,Yingkou 115000,China)

机构地区：[1]营口市中医院肿瘤内科,115000

出　　处：《中国现代药物应用》2024年第12期129-131,共3页Chinese Journal of Modern Drug Application

摘　　要：目的分析在化疗基础上应用卡瑞利珠单抗对晚期食管鳞状细胞癌(ESCC)患者近期疗效的影响。方法晚期食管鳞状细胞癌患者68例,采用随机法将其分为对照组(35例)和观察组(33例)。对照组患者给予单纯化疗,观察组在单纯化疗基础上加用卡瑞利珠单抗治疗。比较两组患者临床疗效、不良反应发生情况以及治疗前后的血清肿瘤标志物[癌胚抗原(CEA)、鳞状上皮细胞癌抗原(SCC-Ag)、细胞角蛋白19片段抗原21-1(CYFRA21-1)]水平。结果治疗后,与对照组的34.29%、51.43%相比,观察组的客观缓解率(ORR)60.61%、疾病控制率(DCR)81.82%明显更高(P<0.05)。治疗后,两组患者CEA、SCC-Ag、CYFRA21-1水平较治疗前均明显下降,且观察组下降幅度较对照组更明显(P<0.05)。两组患者在不良反应发生率方面比较并未见显著差异(P>0.05)。结论卡瑞利珠单抗联合化疗治疗晚期食管鳞状细胞癌患者,能够显著降低患者相关肿瘤标志物水平,缓解临床症状,提高治疗效果,并且未见明显不良反应,值得临床推荐和使用。Objective To analyze the impact of camrelizumab combined with chemotherapy on short-term efficacy of patients with advanced esophageal squamous cell carcinoma(ESCC).Methods 68 patients with advanced esophageal squamous cell carcinoma were randomly divided into a control group(35 cases)and an observation group(33 cases).The control group was treated with chemotherapy alone,and the observation group was treated with camrelizumab on the basis of chemotherapy.Patients in both groups were compared in terms of clinical efficacy,occurrence of adverse reactions and serum tumor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag),cytokeratin fragment antigen 21-1(CYFRA21-1)]before and after treatment.Results After treatment,the objective remission rate(ORR)and disease control rate(DCR)in the observation group were 60.61%and 81.82%,which were significantly higher than 34.29%and 51.43%in the control group(P<0.05).After treatment,the levels of CEA,SCC-Ag and CYFRA21-1 in both groups were significantly decreased compared with those before treatment,and the magnitude of decrease in the observation group was more significant than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Camrelizumab combined with chemotherapy for the treatment of patients with advanced esophageal squamous cell carcinoma can significantly reduce the levels of relevant tumor markers of patients,alleviate the clinical symptoms,improve the therapeutic effect,and no obvious adverse reactions have been seen,which is worthy of clinical recommendation and use.

关 键 词：食管鳞状细胞癌 放疗 卡瑞利珠单抗 临床疗效 安全性 

分 类 号：R735.1[医药卫生—肿瘤]